Health researchers and reproductive medicine experts challenge a controversial report alleging high complication rates tied to mifepristone, warning that flawed data could distort public understanding and national policy debates.
Peer-reviewed studies show a far lower rate of serious problems.
Republicans cited the statistic last week while discussing court rulings on medication abortion. The Louisiana-based 5th U.S. Circuit Court of Appeals halted access to mifepristone by mail on May 1, but the Supreme Court temporarily restored access on May 4 for a week. On May 11, the court extended its order through May 14.
Rep. Riley Moore of West Virginia in an X post that same day called the drug “extremely dangerous” while referring to a thread from a year prior that claimed “1 in 10 women had dangerous complications like sepsis or hemorrhaging,” based on an April 2025 report from the Ethics and Public Policy Center, a conservative nonprofit that opposes abortion.
